Subscribe to stay informed!
A Devon pharmaceutical company is working on cannabinoid therapies to treat genetic conditions. In the meantime, Zynerba Pharmaceuticals is planning a reverse stock split by…
Before we send you to this site, please subscribe to our daily newsletter.